Abstract 14911: Development and Implantation of Tissue Engineered Self expandable Aortic Stent Grafts (bio Stent Grafts) Using In-body Tissue Architecture Technology in Beagles
Background: Endovascular aortic repair became important treatment option, among aortic surgery with excellent outcomes. Although, endoleaks and migration remains as an issue to be mortified, and stent graft which assimilates to native aorta is desirable. We have developed autologous prosthetic tissues using “in-body tissue architecture” technology, which is a novel and practical approach based on the tissue encapsulation phenomenon of foreign materials in living bodies. Using this technology, we have fabricated the connective tissue covered stent grafts (bio stent grafts;BSGs), which is expected to show good biocompatibility.
Materials and Methods: The preparation mold was assembled by insertion of an acryl rod (diameter: 8.6 mm, length: 40 mm) into a self-expanding nitinol stent (diameter: 9.0 mm, length: 35 mm). The molds (n=9) were embedded into the subcutaneous pouches of 3 beagles for 4 weeks. Upon trimming the excessive tissue and removing each rod, BSGs were obtained. Of 9 stent grafts, 3 were implanted to infrarenal abdominal aorta of the beagles via femoral artery. Aortogram and examination of aortic specimen was performed 30 days after implantation.
Results: The stent strut was completely surrounded by the connective tissue membrane. (Fig. A) The graft wall of the BSG possessed an elastic modulus that was almost two times higher than that of the native beagle aorta. BSGs were delivered accurately to beagle’s abdominal aorta. After 30 days, stent graft assimilated to the native aorta, and neoendothelialization had occurred in all the luminal surface (Fig. B and C). In α-SMA staining of sections from the grafts, a number of SMA-positive cells (cherry red) were observed in the BSG wall and neointima(Fig.D).
Conclusions: We developed and implanted a stent grafts (BSGs) using the in body tissue architecture technology. This BSG is expected to exhibit excellent biocompatibility after being implanted in the aorta, which might reduce the risk of endoleaks or migration.
Author Disclosures: H. Kawajiri: None. T. Mizuno: None. T. Moriwaki: None. R. Iwai: None. K. Kanda: None. H. Yaku: None. Y. Nakayama: None.
- © 2014 by American Heart Association, Inc.